Merck names Paolo Carli as the head of MEA

26 September 2017

Germany’s Merck KGaA (MRK: DE) has appointed Paolo Carli as head of Middle East, Africa & Turkey (MEA) region for its healthcare business. He will be responsible for leading the commercial operations for Merck across the MEA.

Commenting on his appointment Mr Carli said: "Merck prepares to celebrate its 350th year in the pharmaceutical business in 2018. Being a strategic region for Merck, we are committed to excel innovation and create value for patients across this region. I am delighted to lead the MEA team. Our innovative treatment options and sustainable commitment for patients will move us to the next level."

Mr Carli joined Merck in 2008, as the member of the mergers and acquisitions team in Darmstadt, Germany. In that role, he actively participated in the execution of key transactions for the Merck Group. He successfully led Middle East and Egypt in the last five years and now expands his responsibilities to Turkey and Africa.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK